Sveriges mest populära poddar
BioCentury This Week
VetenskapLife Science

Ep. 148 - East-West Summit Highlights Part 2

23 min•18 november 2022

As China’s biopharma companies experience their first “biotech winter,” they should be engaged in active portfolio management, stopping projects that will not meet their investors’ expectations, Agio Capital General Manager Henk Joos said on BioCentury This Week. On a special East-West Summit edition of the podcast, Joos and Immune-Onc Therapeutics founder and CEO Charlene Liao discussed pipeline prioritization and other company survival tactics during today’s difficult financing environment.

Reach us by sending a text

Fler avsnitt av BioCentury This Week

Visa alla avsnitt av BioCentury This Week
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
•29 min
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
•34 min
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
•25 min
Ep. 354 - East-West Summit Takeaways
•26 min
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
•37 min
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
•35 min
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
•35 min
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
•26 min
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
•34 min
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
•31 min

BioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.